NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Short Interest Update

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) saw a large drop in short interest in January. As of January 30th, there was short interest totaling 2,782,413 shares, a drop of 21.1% from the January 15th total of 3,527,843 shares. Currently, 11.6% of the shares of the company are sold short. Based on an average daily volume of 735,544 shares, the short-interest ratio is currently 3.8 days. Based on an average daily volume of 735,544 shares, the short-interest ratio is currently 3.8 days. Currently, 11.6% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a report on Wednesday, January 21st. BTIG Research restated a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a research note on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. D. Boral Capital reissued a “buy” rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a report on Monday, January 5th. Finally, Ascendiant Capital Markets restated a “buy” rating and set a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. Four research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, NRx Pharmaceuticals currently has an average rating of “Hold” and an average target price of $36.75.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in NRXP. Ethos Financial Group LLC acquired a new stake in shares of NRx Pharmaceuticals during the 3rd quarter worth approximately $39,000. Sjbenen Advisory LLC purchased a new position in NRx Pharmaceuticals in the fourth quarter worth approximately $41,000. One Wealth Management Investment & Advisory Services LLC increased its stake in NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after acquiring an additional 12,950 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in NRx Pharmaceuticals in the fourth quarter valued at $107,000. Finally, Two Sigma Investments LP lifted its stake in shares of NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares during the last quarter. 4.27% of the stock is owned by institutional investors and hedge funds.

NRx Pharmaceuticals Stock Up 4.0%

Shares of NRXP stock traded up $0.07 during mid-day trading on Friday, hitting $1.80. 258,351 shares of the stock were exchanged, compared to its average volume of 610,822. NRx Pharmaceuticals has a 52-week low of $1.58 and a 52-week high of $3.84. The company has a market cap of $53.28 million, a PE ratio of -0.77 and a beta of 1.91. The firm has a fifty day moving average of $2.22 and a 200 day moving average of $2.58.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $6.83 million. Equities analysts predict that NRx Pharmaceuticals will post -1.75 EPS for the current year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.